NCT06860152 Cochlear Implant Speech in Noise Processing
| NCT ID | NCT06860152 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Craig D. Workman, PhD |
| Condition | Hearing Loss, Adult-Onset |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-11-14 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-11-14 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will help us in understanding the neural mechanisms by which listeners with a cochlear implant detect speech in noisy environments.
Eligibility Criteria
Cochlear Implant subjects (enrollment is planned at N=120) - Inclusion criteria: 1. Between 18 and 99 years of age. 2. Have a cochlear implant activated for more than one year. 3. Eligible for research under the Iowa Cochlear Implant Project VIII. 4. Ability to understand and willingness to sign a written informed consent document. 5. Severe hearing loss after age 16. Normal Hearing subjects (enrollment is planned at N=30) - Inclusion criteria: 1. Between 18 and 99 years of age. 2. Have age typical hearing. 3. Eligible for research under the Iowa Cochlear Implant Project VIII. 4. Ability to understand and willingness to sign a written informed consent document. Exclusion criteria (all groups): 1. Medical history includes seizure disorder, head injury, neurologic, metabolic, cardiovascular disease, or previous cerebrovascular event (unless approved by PI). 2. Female self-reporting pregnancy. A urine pregnancy test will be performed prior to injection of the radiopharmaceutical. 3. Currently taking medications which may affect cerebral blood flow (e.g., papaverine, ginkgo biloba, acetazolamide). 4. Uncontrolled intercurrent illness that would limit compliance with study requirements per investigator.
Contact & Investigator
Craig D. Workman, PhD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT06860152 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Hearing Loss, Adult-Onset. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06860152 currently recruiting?
Yes, NCT06860152 is actively recruiting participants. Contact the research team at craig-workman@uiowa.edu for enrollment information.
Where is the NCT06860152 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT06860152 clinical trial?
NCT06860152 is sponsored by Craig D. Workman, PhD. The principal investigator is Craig D. Workman, PhD at University of Iowa. The trial plans to enroll 150 participants.